Frontline Use of Erythroid Maturating Agent (EMA): Luspatercept

home / case-based-peer-perspectives / frontline-use-of-erythroid-maturating-agent-luspatercept

Solly Chedid, MD, presents a case of a patient with lower-risk MDS and provides clinical insights on the first-line use of an erythroid maturating agent.

Solly Chedid, MD, an expert on MDS

EP. 1: Approach to 1L Therapy Selection in Lower-Risk MDS

Solly Chedid, MD
August 27th 2024

Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia.

Watch

Solly Chedid, MD, an expert on MDS

EP. 2: Efficacy and Safety Findings from the COMMAND Study

Solly Chedid, MD
August 27th 2024

A hematologist-oncologist discusses the efficacy and safety findings from the COMMANDS trial and how they inform treatment selection.

Watch

Solly Chedid, MD, an expert on MDS

EP. 3: Assessing QoL in MDS Patients

Solly Chedid, MD
August 27th 2024

Solly Chedid, MD, provides clinical insights on quality-of-life assessment practices for patients with MDS.

Watch

Solly Chedid, MD, an expert on MDS

EP. 4: Clinical Benefit of Luspatercept Dose Titration: Real-World Evidence

Solly Chedid, MD
August 27th 2024

An expert on myelodysplastic syndromes reviews recent real-world data presented at EHA 2024 showing the clinical benefit of luspatercept dose titration.

Watch

Solly Chedid, MD, an expert on MDS

EP. 5: Key Takeaways and Unmet Needs in Lower-Risk MDS Anemia Management

Solly Chedid, MD
August 27th 2024

Solly Chedid, MD, shares insights on optimizing anemia management in patients with lower-risk MDS and outlines remaining unmet needs in treating anemia.

Watch